Apomorphine hydrochloride for the treatment of Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2015-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.2015.1051468PMID 26037961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Management of constipation in Parkinson’s disease

  2015cited by this paper
• Apomorphine Penject – Emerging Evidence and Treatment Strategies for Delayed on and off Periods in Parkinson’s disease

  2014cited by this paper
• Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.

  2014cited by this paper
• Delayed gastric emptying in Parkinson's disease

  2014cited by this paper
• Advanced Parkinson's disease: clinical characteristics and treatment. Part II.

  2013cited by this paper
• Advanced Parkinson ’ s disease : Clinical characteristics and treatment ( part 1 )

  2013cited by this paper
• The role of small intestinal bacterial overgrowth in Parkinson's disease

  2013cited by this paper
• Morning Akinesia and the Potential Role of Gastroparesis – Managing Delayed Onset of First Daily Dose of Oral Levodopa in Patients with Parkinson’s Disease

  2013cited by this paper
• Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease.

  2013cited by this paper
• Advanced Parkinson's disease: Clinical characteristics and treatment. Part II

  2013cited by this paper
• Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?

  2013cited by this paper
• Phase IIa randomized double‐blind, placebo‐controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson's disease

  2013cited by this paper
• Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.

  2012cited by this paper
• Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case‐control study

  2010cited by this paper
• Effects of dietary factors on levodopa pharmacokinetics

  2010cited by this paper
• Parkinson's disease (vol 373, pg 2055, 2009)

  2009cited by this paper
• Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating "Off" Episodes in Advanced Parkinson Disease

  2009cited by this paper
• Intermittent Subcutaneous Apomorphine Therapy for ‘Off’ Episodes in Parkinson’s Disease

  2008cited by this paper
• Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.

  2008cited by this paper
• Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study

  2008cited by this paper
• Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.

  2007cited by this paper
• Non-motor Symptoms of Parkinson's Disease

  2007cited by this paper
• Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.

  2007cited by this paper
• Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease

  2006cited by this paper
• Non-motor symptoms of Parkinson's disease: diagnosis and management.

  2006cited by this paper
• Making a case for domperidone in the treatment of gastrointestinal motility disorders.

  2006cited by this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  2006cited by this paper
• Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease

  2006cited by this paper
• Apomorphine in idiopathic restless legs syndrome: an exploratory study

  2005cited by this paper
• A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.

  2005cited by this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cited by this paper
• Rapid treatment of “wearing off” in Parkinson’s disease

  2004cited by this paper
• Subcutaneous Apomorphine

  2004cited by this paper
• Subcutaneously administered apomorphine

  2004cited by this paper
• Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: a preliminary report.

  2003cited by this paper
• Waiting for ON: A Major Problem in Patients With Parkinson Disease and ON/OFF Motor Fluctuations

  2003cited by this paper
• Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment

  2003cited by this paper
• A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

  2001cited by this paper
• Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease

  2000cited by this paper
• A double‐blind, placebo‐controlled study of intranasal apomorphine spray as a rescue agent for off‐states in Parkinson's disease

  1998cited by this paper
• Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up

  1998cited by this paper
• Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment.

  1997cited by this paper
• Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.

  1997cited by this paper
• Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease

  1996cited by this paper
• Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

  1995cited by this paper
• Apomorphine in patients with Parkinson's disease.

  1995cited by this paper
• [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].

  1994cited by this paper
• Defecatory function in Parkinson's disease: Response to apomorphine

  1993cited by this paper
• Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

  1993cited by this paper
• Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.

  1993cited by this paper
• Apomorphine test for dopaminergic responsiveness: A dose assessment study

  1993cited by this paper
• A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.

  1993cited by this paper
• Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.

  1993cited by this paper
• Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification

  1992cited by this paper
• The Motor Response to Repeated Apomorphine Administration in Parkinson's Disease

  1991cited by this paper
• The motor response to sequential apomorphine in parkinsonian fluctuations.

  1991cited by this paper
• Comparison of motor response to apomorphine and levodopa in Parkinson's disease.

  1990cited by this paper
• Subcutaneous apomorphine in the treatment of Parkinson's disease.

  1990cited by this paper
• Anal sphincter dysfunction in Parkinson's disease.

  1989cited by this paper
• Peripheral pharmacokinetics of apomorphine in humans

  1989cited by this paper
• Side-effects of subcutaneous apomorphine in Parkinson's disease.

  1989cited by this paper
• Subcutaneous apomorphine in Parkinson's disease.

  1989cited by this paper
• Side-effects of subcutaneous apomorphine in Parkinson's disease.

  1989cited by this paper
• Interleukins and the immune system 1.

  1989cited by this paper
• Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.

  1988cited by this paper
• Subcutaneous apomorphine in parkinsonian on-off oscillations.

  1988cited by this paper
• Subcutaneous apomorphine in Parkinson's disease.

  1988cited by this paper
• Cardiotoxicity of intravenous, domperidone.

  1985cited by this paper
• Cardiac arrest after treatment with intravenous domperidone.

  1985cited by this paper
• Cardiotoxicity of intravenous domperidone.

  1985cited by this paper
• Prevalence of migraine in patients with diabetes.

  1984cited by this paper
• On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

  1984cited by this paper
• Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone.

  1984cited by this paper
• The use of dopamine agonists in the treatment of schizophrenia.

  1981cited by this paper
• Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

  1979cited by this paper
• epsilon-aminocaproic acid in prevention of subarachnoid haemorrhage.

  1979cited by this paper
• Letter: Motor-neurone disease in Israel.

  1975cited by this paper
• Similarities between neurologic effects of L-dopa and of apomorphine.

  1970cited by this paper
• Apomorphine in Parkinson's disease.

  1951cited by this paper
• Apomorphine in Parkinson's disease.

  1951cited by this paper
• A CLINICAL LECTURE ON SHAKING PALSY

  year unknowncited by this paper

• Palladium-Catalyzed α-Arylation of Esters: Synthesis of the Tetrahydroisoquinoline Ring

  2025cites this paper
• Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson’s Disease: An Open-Label, Randomized, Crossover Study

  2023cites this paper
• Identifying potential drug-target interactions based on ensemble deep learning

  2023cites this paper
• Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.

  2022cites this paper
• A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease

  2022cites this paper
• Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.

  2021cites this paper
• Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson’s disease management in developing countries

  2020cites this paper
• Management with apomorphine in Parkinson's disease

  2020cites this paper
• Tannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice

  2020cites this paper
• Transforming Curry Extract to Liposomal Curcumin (LipocurcTM)in Parkinson Disease (PD) Therapeutics Landscape: EmergingRole of Epigenetics Signaling and Nanotechnology

  2020cites this paper
• Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles

  2020cites this paper
• Identification of C10 nitrogen-containing aporphines with dopamine D1 versus D5 receptor selectivity.

  2020cites this paper
• Apomorphine: The Initial Indian Experience in Relation to Response Tests and Pumps

  2019cites this paper
• Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy.

  2019cites this paper
• Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

  2019cites this paper
• Dopamine regulates cytokine secretion during innate and adaptive immune responses

  2018cites this paper
• [Practical use of continuous apomorphine infusion via pump].

  2017cites this paper
• Exploring the global animal biodiversity in the search for new drugs – Spiders, scorpions, horseshoe crabs, sea spiders, centipedes, and millipedes

  2017cites this paper
• Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients

  2017cites this paper
• Pharmacological Insights into Levodopa‐induced Motor Fluctuations in Patients with Parkinson's Disease

  2016cites this paper
• New and emerging medical therapies in Parkinson’s disease

  2016cites this paper
• Practical management of adverse events related to apomorphine therapy.

  2016cites this paper
• Design and Synthesis of Dopaminergic Agonists.

  2016cites this paper
• Oral r‐(‐)‐11‐o‐valeryl‐n‐n‐propylnoraporphine reverses motor deficits in mptp‐treated marmosets

  2016cites this paper
• A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease

  2016cites this paper